Healthcare
Live Price
Offline$327.95
+1.35% today
1Y Change
+51.73%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
West Pharmaceutical Services, Inc. (WST) is a Healthcare stock with a market cap of $21.21B and listed on NYSE. The stock last traded around $327.95 and up 51.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +6.3%, EPS growth of +1.2%, a dividend yield of 0.3%. What stands out right now is revenue +6.3%, EPS +1.2%, free cash flow +69.6% with operating margin 20.7% and ROIC 15.2%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 39.8 and price/sales 6.6. Stock Foundry combines WST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WST
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WST Max Drawdown
-24.83%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WST and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.8B
-1.9% YoY
FY Net Income
$661.8M
+13.0% YoY
Free Cash Flow
$330.6M
-24.8% YoY
Revenue Growth
+6.3%
EPS Growth
+1.2%
Gross Margin
36.2%
Net Margin
16.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.1B | 2.9B | 3.0B | 2.9B | 2.8B |
| Gross Profit | 1.1B | 1.0B | 1.1B | 1.1B | 1.2B |
| Operating Income | 617M | 595M | 711M | 764M | 759M |
| EBITDA | 724M | 744M | 844M | 808M | 880M |
| Net Income | 494M | 493M | 593M | 586M | 662M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 791M | 485M | 854M | 894M | 763M |
| Total Assets | 4.3B | 3.6B | 3.8B | 3.6B | 3.3B |
| Total Liabilities | 1.1B | 961M | 949M | 932M | 978M |
| Shareholder Equity | 3.2B | 2.7B | 2.9B | 2.7B | 2.3B |
| Total Debt | 417M | 305M | 309M | 318M | 325M |
| Net Debt | -375M | -179M | -545M | -576M | -437M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
584M
-19.3% YoY
Capital Expenditures
253M
+11.0% YoY
Free Cash Flow
331M
-24.8% YoY
Key ratios
Gross Margin
36.2%
Operating Margin
20.7%
Net Margin
16.9%
ROE
17.9%
Debt / Equity
0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.